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Abstract
This article first examines data bases available to assess the risk of vaccine-preventable diseases (VPD).
In the second part, immunization recommendations and practices are briefly evaluated in view of the
risk of exposure to VPD and of the efficacy and safety of available vaccines.
In continuing to assume responsibility for the health of personnel assigned to peace-
keeping missions, the United Nations (UN) issued recommendations for immuniza-
tions to the contingents of the various nations taking part in the United Nations Tran-
sition Assistance Group (UNTAG) in Namibia (10). Authorities in preventive medicine
in the countries recruiting UNTAG forces often, however, decided to add or to delete
immunizations from the UN list. These variations are recorded in Table 1, along with
the UN recommendations. The important differences in immunization programs stem
from different sources. Different data may have been used to compare the impact of
vaccine-preventable diseases (VPD) with the safety, efficacy, and costs of such immu-
nizations on the individual observer or on the entire peacekeeping force. Legal and
social aspects of such intervention may have been influential. Different conclusions
may have been derived from the same data bases. In some cases, older textbooks or
personal opinion may have been the basis for a decision.
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AVAILABLE DATA BASES NEEDED FOR THE DEVELOPMENT
OF RECOMMENDATIONS
Incidence Data on Communicable Diseases
Ideally, data on the incidence of immunizable diseases within a population that has
fulfilled similar duties in the same location should be available. For the UNTAG mis-
sion in Namibia, it was possible to analyze data provided by the South African Med-
ical Services, which surveyed all of the armed forces staying in this country.
When such data are not available, incidence and/or prevalence data generated from
the autochthonous population in the host country may be substituted. Such data, how-
ever, may be misleading. In Namibia, plague is reported to have occurred continu-
ously, with an incidence rate of 8/100,000 in 1987-88 (2), but not a single case has
been observed in the South African Armed Forces. Apparently, all of the cases in the
recent years were diagnosed in natives living in specific areas (M. Isaacson, personal
communication). To determine the threat of given infections, the limited data that are
available should be analyzed in detail by the epidemiological officers who collected
them. Data involving the use of medical services in the host country and claims against
sickness funds appear to be less relevant.
If the civil services have been disrupted in the host country for a period of time,
data may be unavailable or outdated, particularly if the hygienic conditions have changed
greatly since the data were collected. Usually, under such circumstances studying data
from neighboring countries that have similar climatic conditions is of only limited
usefulness. Unfortunately, for determining the risk of contracting immunizable dis-
eases, epidemiological data from previous UN or other missions conducted in the same
areas after the breakdown of hygiene are usually scarce. The data base of the U.S. Peace
Corps is not representative for UN peacekeeping missions (1).
Therefore, it may be worthwhile to consider the risk of immunizable diseases in
travelers who have visited Africa, Asia, Central America, or South America. The respec-
tive data all show that in susceptible persons hepatitis A occurred more often than
typhoid fever and that the incidence of typhoid fever was greater than that of poliomy-
elitis or of cholera (Table 2) (8). It may be speculated that, except possibly in a very
localized epidemic, this sequence of incidence rates will remain constant in all mis-
sions, even if the actual rates may vary according to the hygienic conditions.
Host Factors
Vaccination recommendations must be adapted according to the immunological status
of the populations selected for the mission. Some immunizations might be unneces-
sary for part of the population selected for a mission; for instance, it is unnecessary
to administer immunoglobulin to contingents from countries who in their adult popu-
lations show prevalence rates close to 100% for antibodies against hepatitis A. On
the other hand, some vaccinations that are considered standard procedure in industri-
alized countries may not have been given staff members brought up in developing coun-
tries. Therefore, it is necessary to review prevalence data for selected infections and
data on immunization regulations, including past regulations, in all countries delegating
staff to a peacekeeping mission.
One must also be aware of the tasks and particular exposure that various sub-
populations will have in the peacekeeping mission. In fulfilling their main tasks of
guaranteeing free and fair elections and assisting in the transition to independence,
the UNTAG forces were deployed throughout Namibia. Because they traveled frequently,
the majority had the same exposure to VPD. However, the risk of hepatitis B was cer-
tainly increased in staff who fulfilled medical duties (3).
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Table 2. Morbidity and Mortality of Vaccine-Preventable Diseases in 1 Million Nonimmune
Travelers Visiting Developing Countries8
Infection
Hepatitis A
Hepatitis B
(symptomatic or
asymptomatic)
Typhoid
India, N/NW Africa
Poliomyelitis
Symptomatic
Asymptomatic
Cholera
Mortality/month
3,000(-6,000)
800(-2,400)
30
300
1
20(-1,000)
3
Incidence/month
0.1
2
1
1
20
—
2
Case fatality
rate (%)
3(-6)
16(-48)
0.3
3
0.2
? In contacts
0.06
No data available for diphtheria, Japanese encephalitis, measles, meningococcal meningitis, rabies, teta-
nus, tuberculosis, or yellow fever.
0
 Estimates based on refs. 4; 6; 8; and unpublished data.
Table 3. Synopsis of Immunobiologicals for Use in Staff Recruited for Peacekeeping
Missions
Immunization
Cholera
Diphtheria
Hepatitis A (Ig)b
Hepatitis B
Japanese encephalitis
Measles
Meningococcal
meningitis
Plague
Poliomyelitis
Rabies
Tetanus
Tuberculosis
Typhoid fever
Yellow fever
Application
id/sc/im
im
im
im
im
sc
im
im
po/im
im/(id)
im
ic
po/im
sc
% Efficacy
50
80-98
85
90
90
>95
70-90
90
>99
>99
>99
0-80
70
>99
Effective from
daya
P6, Rl
30
4-7
30-60
7
60
7
few
30
7
30
60
po 15/im(?)
P10, Rl
Duration of
protection
O: 6 mo; E: 3-4 mo
5(-10) yr
4(-6) mo
3-8 yr
1-4 yr
Life(?)
1-3 yr
6 mo
po: >15 yr; im: >5 yr
2-3 yr
10 yr
10(?) yr
po: 6(?) yr; im: 3 yr
O: 10 yr; E: >15 yr
Abbreviations: P = primary; R = revaccination; O = officially; E = effectively.
« If more than one dose necessary, number of days following completion of series.
b
 May possibly provide some protection against hepatitis B and hepatitis non-A, non-B.
Impact of Infection on the Individual and on the Entire Mission
One has to consider how easily an individual infection can be treated under bad en-
vironmental conditions and the nature of the risk of spreading a particular infection
throughout the staff. Tetanus has a bad prognosis unless the patient receives optimal
and costly therapy, which probably includes evacuation. While tetanus will not affect
entire groups of staff, epidemics of meningococcal meningitis may break out in a
crowded setting.
Safety and Efficacy of Vaccines and Immunoglobulins
Vaccines that may be considered for immunization of staff recruited for peacekeeping
missions are listed in Table 3. In summary, these vaccines are safe, but the degree of
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efficacy varies among them. Cholera vaccine, in particular, is of uncertain efficacy.
The efficacy of Ty21a oral typhoid vaccine appears to be inconsistent, according to
the data that have recently been reviewed (5;6;7).
Cost-Benefit Evaluation
Recently, Wiedermann (9) at the University of Vienna compared the cost of disease
and of vaccination by using the formula
Cv + (1 - p)Cn-Rm + (1 - P)CLRL '
in which Qc stands for the cost-benefit ratio, Cn the cost of therapy, Cv the cost of
vaccination, Rm the risk of morbidity, RL the risk of fatality, CL the cost of fatal out-
come, and p the protection rate afforded by the vaccine. Of course, the values for Qc
vary greatly according to the risks and the costs for different populations and for
different risk settings, but a crude estimate is shown in the following two examples.
For cholera, Cn in the field per patient and costs for incapacity to work for half
a month may be US $2,500; Rm may be 4/100,000 per year; CL may be US $1,000,000;
and RL in such a setting may be 2% of Rm (4), which corresponds to 0.08/100,000
per year. CV for two doses per year, including staff and material, may be US $10; p
is approximately 0.5. Qc = 0.09, which is clearly below 1; this vaccine is thus not cost-
beneficial.
For hepatitis A, Cn in the field per patient and costs for incapacity to work for
a month may be US $5,000; Rm may be 600/100,000 per year; CL may be US
$1,000,000; and RL may be 0.01 <% of Rm, which corresponds to 0.06/100,000 per year.
Cv for three doses per year, including staff and material, may be US $30; p has been
shown to be approximately 0.85. Qc = 1.002; this immunization would thus be just
cost-beneficial, particularly if we consider that the hygienic conditions may be even
less favorable than for travelers (Table 2), from whom the data were derived.
Legal Aspects
Contrary to an old belief, only a very few countries require cholera vaccination certifi-
cates from travelers arriving from endemic areas. As of June 1991, they were only Kenya
and Tanzania (Zanzibar and Pemba). Therefore, only staff from these two countries
should be vaccinated either before leaving home or at least 6 days before returning
home from an assignment in an endemic area. No proof of cholera vaccination is neces-
sary anywhere in the world for staff arriving from nonendemic countries, with the
exception of Pemba and Zanzibar (Tanzania).
Egypt, India, and Pakistan consider the whole territory of any country in the yellow
fever endemic zone of Africa and South America (10) to be infected with yellow fever
and, therefore, demand a yellow fever vaccination certificate from travelers coming
from, for example, Kenya. Therefore, staff entering or returning to those three nations
from such African or South American countries need to have been vaccinated at least
10 days before arrival.
RECOMMENDATIONS FOR IMMUNIZATIONS IN PEACEKEEPING MISSIONS
In general, there is a need for uniform policies. Otherwise, members from different
contingents may understandably express doubts about the competence or the sense
of responsibility of those who have decided about immunization programs. It may
be wise to consult the responsible experts in the various countries sending contingents.
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Intelligence on disease risks, generated prior to deployment, is needed to reach a con-
sensus. Continuous surveillance of morbidity and mortality is necessary. It would be
helpful if UN headquarters would prescribe a standardized surveillance scheme.
Presumably, there will also be a lack of data for future peacekeeping missions.
Current data for the various immunizations are summarized in alphabetical order in
Table 4. Staff recruited for peacekeeping missions should be given only the necessary
immunizations, and should not be subjected to either the potential adverse reactions
or the inconvenience of unnecessary measures. Above all, they should not be immunized
against rare infections while being left unprotected against frequent ones, particularly
when the latter have a similar fatality rate per case. This discretion might also save
costs to the sponsoring organization.
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